Skip to content

The effect of melatonin supplement on blood levels of PD-1 in patients with rheumatoid arthritis

Effects of melatonin supplementation on serum Programmed death (PD-?1) in rheumatoid arthritis patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250202064605N1
Enrollment
50
Registered
2025-10-25
Start date
2025-11-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: The intervention group includes patients with rheumatoid arthritis who will continue their routine therapy including methotrexate (7.5-25 mg/weekly), prednisolone (

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Definite diagnosis of rheumatoid arthritis according to the American College of Rheumatology criteria and DAS28 score Patients in the early phase of diagnosis (before major therapeutic changes) Receiving stable doses of standard triple therapy including methotrexate, prednisolone, and hydroxychloroquine No use of vitamin supplements or antioxidant compounds within the last two months Willingness and ability to participate in the study and providing written informed consent

Exclusion criteria

Exclusion criteria: Presence of other autoimmune diseases, uncontrolled hypertension, diabetes, heart failure, chronic kidney disease, hepatic or endocrine disorders Pregnancy or lactation Use of sedative drugs, oral contraceptives, antioxidant supplements, or omega-3 during the past month Smoking or alcohol consumption Body mass index > 30 kg/m2 Known hypersensitivity to melatonin

Design outcomes

Primary

MeasureTime frame
Change in serum PD-1 level. Timepoint: At baseline and 12 weeks after intervention. Method of measurement: 5 milliliter of fasting venous blood will drone and after serum separation, serum level of PD-1 using a commercial ELISA kit per manufacturer’s instructions will be measured. All assays performed in the same laboratory and preferably with a single lot.

Secondary

MeasureTime frame
Clinical signs and disease activity. Timepoint: At baseline and 12 weeks after intervention. Method of measurement: DAS28 score will be calculated based on the count of 28 tender and swollen joints, erythrocyte sedimentation rate or C-reactive protein, and patient’s global assessment using a visual analogue scale. All assessments will be performed by a rheumatologist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Nakhjawani

Tabriz University of Medical Sciences

Mdrmrjn@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026